IBRX
ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.42
−8.28%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 16.10x
- P/S forward
- 29.17x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -8.53x
- Price / sales
- 53.83x
- Price / cash flow
- -31.74x
Enterprise value
- Enterprise value
- $9.4B
- EV / sales
- 56.58x
- EV / EBITDA
- -10.51x
- EV / EBIT
- -37.25x
- Market cap
- $8.9B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026